Articles by Hana Safah, MD

BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

Quadruplet Combination Therapies in Relapsed Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

Strategies for Treatment of Multiple Myeloma at Late Relapse
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD The panel debates the options for treatment of late relapsed multiple myeloma.

Data Updates in the Treatment of Relapsed Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Relapse in Multiple Myeloma: Biochemical and Chemical
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Defining Frailty in Multiple Myeloma for Optimal Treatment
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.